Cullinan Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Cullinan Therapeutics, Inc. (CGEM) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-167.58-155.10111.21-65.57-51.80
Depreciation & Amortization0.310.310.090.050.06
Stock Based Compensation37.8230.4427.9624.3814.91
Change in Working Capital-0.39-0.3411.18-3.546.85
Change in Accounts Payable-0.81-4.45-0.51-4.845.58
Change in Other Working Capital0.420.137.401.291.27
Other Operating Activities-15.470.13-2.02-1.85-6.48
Net Cash from Operating Activities-145.30-134.28-126.66-43.43-29.77
Investing Activities
Capital Expenditures0.00-0.21-1.130.00-0.01
Purchases of Investments-721.13-373.38-24.98-333.78-6.86
Sales/Maturities of Investments584.82409.40250.02192.040.00
Other Investing Activities0.000.00275.000.001.45
Net Cash from Investing Activities-136.3135.81248.98-333.78-5.42
Financing Activities
Debt Repayment0.000.00-2.200.000.00
Common Stock Issued262.6538.396.02270.55145.51
Other Financing Activities3.540.00-32.13-1.77-5.37
Net Cash from Financing Activities266.1940.75-25.93268.78140.14
Summary
Net Change in Cash-15.43-57.7296.38-108.42104.95
Cash at Beginning of Period98.43156.1559.77168.200.00
Cash at End of Period83.0198.43156.1559.770.00
Free Cash Flow-145.30-134.48-127.80-43.43-29.78
Supplemental Disclosures
Interest Paid0.000.000.030.000.00
Income Taxes Paid-2.27-4.4337.800.000.00